IP Library Granted Patent US 11,845,968
Granted Patent B2
US 11,845,968 · App. 17/592,869 · Granted Dec 19, 2023

Engineered deoxyribose-phosphate aldolases

Inventors: Da Duan (Newark, CA); Oscar Alvizo (Fremont, CA); Jovana Nazor (Milpitas, CA); Harvinder Chagger Maniar (Hayward, CA); James Nicholas Riggins (San Francisco, CA); Jonathan Vroom (South San Francisco, CA); Santhosh Sivaramakrishnan (Redwood City, CA); Hao Yang (Rahway, NJ); Anna Fryszkowska (New York, NY); Mark A. Huffman (Rahway, NJ); Joshua N. Kolev (Rahway, NJ); Iman Farasat (Rahway, NJ); Agustina Rodriguez-Granillo (Rahway, NJ); Deeptak Verma (Rahway, NJ)
Assignee: Codexis, Inc.
C12N9/88C12N15/63C12P21/02C12Y401/02004
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,845,968
App. No.
17/592,869
Granted
Dec 19, 2023
Kind
B2
Abstract

The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.

Claims (14)

1. An engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase, wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 2, or a functional fragment thereof, wherein said engineered deoxyribose-phosphate aldolase comprises a substitution in said polypeptide sequence of X145C/R/K, and wherein said engineered deoxyribose-phosphate aldolase has at 1.2 fold increase activity on (R)-2-ethynyl-glyceraldehyde compared to the deoxyribose-phosphate aldolase of SEQ ID NO:2, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2.

2. The engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase further comprises at least one substitution or set of substitutions in said polypeptide sequence at one or more positions selected from 2, 2/6/10/66/88/102/184/235/236, 2/6/102/141/203/235, 2/10/102/235/236, 2/47/66/71/141/184/203/235/236, 2/47/71/88/203/235/236, 2/47/71/141/197/235/236, 2/88/141/235/236, 2/203/235/236, 5, 6/203/235/236, 9, 10/47/66/184/197/236, 10/47/66/235/236, 10/47/71/184/203/235/236, 13, 13/46, 13/46/66/94, 13/46/66/94/184/204, 13/46/66/133/134/184, 13/46/66/184, 13/46/112/134/184, 13/46/133/184, 13/66/94, 13/66/94/184, 13/66/112/133/134/184/204, 13/66/112/133/134/204, 13/66/112/184, 13/66/133/134/184/204, 13/66/184/204, 13/94/133/184, 13/94/184, 13/94/184/204, 13/133/134/184, 13/133/134/204, 13/134/204, 13/184, 27, 40, 46/66/94/112, 46/66/112/133/134/184, 46/66/133/134, 46/66/133/184/197, 46/66/133/197, 46/66/134/184/197/204, 46/66/184, 46/112/133, 46/112/133/134/204, 46/133/204, 46/197/204, 47/66/71/88/203/235/236, 47/66/71/141/184, 47/66/88/184/235, 47/66/88/203/235/236, 47/66/141/235/236, 47/66/184/197/203/235/236, 47/66/184/197/236, 47/71/88/184/203/235, 47/71/88/184/203/236, 47/71/141/184/203/235, 47/71/184, 47/71/184/197/236, 47/71/184/235, 47/71/184/236, 47/88/102/141/235/236, 47/88/203/235/236, 47/88/235/236, 47/102/184/197/235/236, 47/102/203/235/236, 47/141/184, 47/141/184/236, 47/184/236, 47/203/235, 47/203/235/236, 47/203/236, 47/235/236, 62, 66, 66/88/102/184/197/203/235/236, 66/88/197, 66/88/235, 66/88/235/236, 66/94, 66/94/112/133/184, 66/94/112/184/204, 66/102/184/235/236, 66/112/133/134/197, 66/112/133/197, 66/112/134/197, 66/112/184, 66/133/184, 66/133/197, 66/184, 66/197/203/235, 84, 88, 88/102/141/184/235/236, 88/184, 88/184/197/203/235/236, 88/184/197/235/236, 88/184/203/235, 88/184/236, 88/197/235/236, 88/236, 94/112/184/197, 94/133/184, 96, 102/141/203, 102/184/203/236, 102/184/236, 102/197/235, 112, 112/133/134, 112/133/184/204, 112/134/197, 114, 115, 120, 127, 132, 133, 133/134/184, 141/184/203/235/236, 141/184/235, 141/197, 141/203/235/236, 141/236, 146, 148, 184, 184/203, 184/203/235, 184/203/236, 184/235/236, 184/236, 197/235, 203/235/236, 203/236, 204, 218, 235, 235/236, and 236, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 6.

3. The engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase further comprises at least one substitution or set of substitutions in said polypeptide sequence at one or more positions selected from 71/88/94/133, 71/133, and 133, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 466.

4. The engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence that is at least 95% identical to the sequence of at least one engineered deoxyribose-phosphate aldolase variant set forth in the even numbered sequences of SEQ ID NOs: 6, 12, 42, 104, 140-478.

5. The engineered polynucleotide encoding an engineered deoxyribose-phosphate aldolase of claim 1 , wherein said engineered deoxyribose-phosphate aldolase comprises a polypeptide sequence set forth in the even numbered sequences of SEQ ID NOs: 6, 12, 42, 104, 140-478.

6. The engineered polynucleotide sequence of claim 1 , wherein said engineered polynucleotide sequence comprises a sequence set forth in the odd numbered sequences of SEQ ID NOs: 5, 11, 41, 103, 139-477.

7. The engineered polynucleotide sequence of claim 1 , wherein said polynucleotide sequence is operably linked to a control sequence.

8. The engineered polynucleotide sequence of claim 1 , wherein said engineered polynucleotide sequence is codon optimized.

9. An expression vector comprising at least one polynucleotide sequence of claim 1 .

10. A host cell comprising at least one expression vector of claim 9 .

11. A host cell comprising at least one polynucleotide sequence of claim 1 .

12. A method of producing an engineered deoxyribose-phosphate aldolase in a host cell, comprising culturing the host cell of claim 11 , in a culture medium under suitable conditions, such that at least one engineered deoxyribose-phosphate aldolase is produced.

13. The method of claim 12 , further comprising recovering at least one engineered deoxyribose-phosphate aldolase from the culture medium and/or host cell.

14. The method of claim 13 , further comprising the step of purifying said at least one engineered deoxyribose-phosphate aldolase.

Assignments (2)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2023
From: DUAN, DA; ALVIZO, OSCAR; NAZOR, JOVANA; MANIAR, HARVINDER CHAGGER; RIGGINS, JAMES NICHOLAS; VROOM, JONATHAN; SIVARAMAKRISHNAN, SANTHOSH
To: CODEXIS, INC.
Reel/Frame 065483/0295 →
Continuity (4)
Division 16460118 · Jul 2, 2019
Provisional Application 62822273 · Mar 22, 2019
Provisional Application 62695520 · Jul 9, 2018
Related Publication 20220162580A1 · May 26, 2022
Cited By (1)
US 12,460,195